• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

PHAR

Partnership for Health Analytic Research

  • Services
    • Real World Data: Secondary Data Analysis
    • Real World Data: Primary Data Collection
    • Evidence Synthesis
  • Publications
  • Clients
  • Team
  • News
  • Contact

Primary Sidebar

News Categories

  • Presentations & Events
  • Awards & Recognition
  • Publications
  • News & Announcements

Archive

  • 2022
  • 2021
  • 2020
  • 2019

Use of 12-gene colon cancer recurrence score assay may lead to reduction in treatment intensity

Given the small magnitude of benefit with adjuvant therapy in stage II colon cancer, chemotherapy is often selected for patients based on their physicians’ subjective assessment of clinical factors. To help guide oncologists’ adjuvant treatment recommendations for standard risk patients where other existing markers are not informative, the 12-gene colon cancer Oncotype DX® Recurrence Score® Assay was developed. The investigators at PHAR in collaboration with Genomic Health studied the effects of the assays by conducting physician surveys. U.S. medical oncologists who ordered the assay for ≥3 stage II colon cancer patients were asked to complete a web-based survey regarding their most recent such patient. They found that the use of the Oncotype DX assay is associated with an overall change of nearly one in three treatment recommendations for stage II colon cancer patients, and that it may lead to more appropriate use of adjuvant treatment. The study can be read here.

November 13, 2013 | Publications

Partnership for Health Analytic Research

Beverly Hills
Cambridge
San Francisco
info@pharllc.com
310.858.9555
pharllc.com
  • Employment
  • Contact
  • Privacy Policy
Design by Studio Rainwater
© PHAR 2023